id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_4iwqrs2pf5bc5hx2wlsa4ykoky	Erik Serrao	Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors	2009	14	.pdf	application/pdf	11046	1423	50	development of raltegravir, HAART had been recommended to consist of at least three different drugs targeting separate stages of the HIV life cycle: two nucleoside Simultaneously, a different group discovered and developed potent DKA compounds, leading to both the first Although raltegravir has become a modern blockbuster anti-HIV drug, multiple viral amino acid mutations profiles (compound 18 = 12 nM IC50 against strand transfer, 86 nM CIC95 in cells in 50% NHS, and a 47% bioavailability and 48 mL/min/kg plasma clearance in rats). of a new HIV-1 integrase inhibitor in clinical development. activity of MK-0518, a potent HIV integrase inhibitor. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. M, Summa V: Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable Nof raltegravir, a potent, selective orally bioavailable HIVintegrase inhibitor for the treatment of HIV-AIDS infection. resistance profile of a novel HIV integrase inhibitor JTK-303/	./cache/work_4iwqrs2pf5bc5hx2wlsa4ykoky.pdf	./txt/work_4iwqrs2pf5bc5hx2wlsa4ykoky.txt